68 related articles for article (PubMed ID: 10079062)
1. Review of intravenous immunoglobulin replacement therapy trials for primary humoral immunodeficiency patients.
Schroeder HW; Dougherty CJ
Infection; 2012 Dec; 40(6):601-11. PubMed ID: 22968971
[TBL] [Abstract][Full Text] [Related]
2. Dealing with a critical national shortage-Approaches to triaging immune globulin supply in pediatric hematology and oncology.
Edington HJ; Sutton KS; Bennett C; Chandrakasan S; Sterner-Allison J; Castellino SM
Pediatr Blood Cancer; 2020 Jul; 67(7):e28260. PubMed ID: 32329568
[No Abstract] [Full Text] [Related]
3. More a hammer than a mirror.
Emmanuel A
Clin Med (Lond); 2019 May; 19(3):193. PubMed ID: 31092509
[No Abstract] [Full Text] [Related]
4. Safety, efficacy, and pharmacokinetics of Flebogamma 5% [immune globulin intravenous (human)] for replacement therapy in primary immunodeficiency diseases.
Berger M; Pinciaro PJ;
J Clin Immunol; 2004 Jul; 24(4):389-96. PubMed ID: 15163895
[TBL] [Abstract][Full Text] [Related]
5. The product: All intravenous immunoglobulins are not equivalent.
Siegel J
Pharmacotherapy; 2005 Nov; 25(11 Pt 2):78S-84S. PubMed ID: 16229678
[TBL] [Abstract][Full Text] [Related]
6. The pocketbook: Pharmacoeconomic issues related to intravenous immunoglobulin therapy.
Mahadevia PJ
Pharmacotherapy; 2005 Nov; 25(11 Pt 2):94S-100S. PubMed ID: 16229680
[TBL] [Abstract][Full Text] [Related]
7. Renal insufficiency and failure associated with immune globulin intravenous therapy--United States, 1985-1998.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 1999 Jun; 48(24):518-21. PubMed ID: 10401909
[TBL] [Abstract][Full Text] [Related]
8. Availability of immune globulin intravenous for treatment of immune deficient patients--United States, 1997-1998.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 1999 Mar; 48(8):159-62. PubMed ID: 10079062
[TBL] [Abstract][Full Text] [Related]
9. The patient: Emerging clinical applications of intravenous immunoglobulin.
Harvey RD
Pharmacotherapy; 2005 Nov; 25(11 Pt 2):85S-93S. PubMed ID: 16229679
[TBL] [Abstract][Full Text] [Related]
10. Information for healthcare providers on general features of IGIV with emphasis on differences between commercially available products.
Gürcan HM; Keskin DB; Ahmed AR
Autoimmun Rev; 2010 Jun; 9(8):553-9. PubMed ID: 20346419
[TBL] [Abstract][Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
